Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 2Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Leukemia, Myeloid, Acute 2Pancreatic Neoplasms 1Leukemia, Myelomonocytic, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Gemcitabine 74Fluorouracil 31Oxaliplatin 21Leucovorin 21130-nm albumin-bound paclitaxel 17Capecitabine 14Irinotecan 12Albumin-Bound Paclitaxel 10irinotecan sucrosofate 8Radiotherapy 6Taxes 5Erlotinib Hydrochloride 5folfirinox 4rubitecan 3Surgical Procedures, Operative 3Specimen Handling 3Pancreaticojejunostomy 3Neoadjuvant Therapy 3Drug Therapy 3Cisplatin 3Chemotherapy, Adjuvant 3ruxolitinib 2masitinib 2dehydroftorafur 2Saline Solution 2S 1 (combination) 2Paclitaxel 2GV1001 peptide 2Fentanyl 2Bevacizumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Pancreatic Neoplasms × tipifarnib × Clear all
NCT00005648 2011-05-19

Gemcitabine With or Without Tipifarnib (R115777) in Treating Patients With Advanced Pancreatic Cancer

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Phase 3 Completed
688 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡